India, July 15 -- VivoSim Labs, Inc. (VIVS) shares rose 16.81 percent, gaining $0.14 to trade at $0.9751 on Wednesday, after the company announced a $5 million milestone payment from Eli Lilly and projected more than 500 percent revenue growth for fiscal 2027.
The stock opened at $1.49 and traded between $0.9081 and $1.57 during the session on the Nasdaq. It has traded in a 52-week range of $0.78 to $5.30. Trading volume reached 95.02 million shares, compared with an average daily volume of 92,604 shares.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The payment is tied to a former inflammatory bowel disease drug program that VivoSim previously sold to Eli Lilly and was triggered by the dosing of th...